Dr. Julie Graff, MD
Claim this profileVA Portland Health Care System, Portland, OR
Studies Prostate Cancer
Studies Fanconi Anemia
5 reported clinical trials
9 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
RAD51 positive
RAD51C positive
2Fanconi Anemia
Stage IV
RAD51 positive
RAD51C positive
Affiliated Hospitals
Clinical Trials Julie Graff, MD is currently running
High Dose Testosterone
for Prostate Cancer
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Recruiting3 awards Phase 2
Registry
for Advanced Prostate Cancer
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Recruiting1 award N/A5 criteria
More about Julie Graff, MD
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Julie Graff, MD has experience with
- Abiraterone Acetate
- Apalutamide
- Prednisone
- Carboplatin
- Olaparib
- High Dose Testosterone
Breakdown of trials Julie Graff, MD has run
Prostate Cancer
Fanconi Anemia
Hereditary Sensory Neuropathy
Breast and ovarian cancer syndrome
RAD51 Gene Mutation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Julie Graff, MD specialize in?
Julie Graff, MD focuses on Prostate Cancer and Fanconi Anemia. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are RAD51 positive.
Is Julie Graff, MD currently recruiting for clinical trials?
Yes, Julie Graff, MD is currently recruiting for 3 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Julie Graff, MD has studied deeply?
Yes, Julie Graff, MD has studied treatments such as Abiraterone Acetate, Apalutamide, Prednisone.
What is the best way to schedule an appointment with Julie Graff, MD?
Apply for one of the trials that Julie Graff, MD is conducting.
What is the office address of Julie Graff, MD?
The office of Julie Graff, MD is located at: VA Portland Health Care System, Portland, OR, Portland, Oregon 97239 United States. This is the address for their practice at the VA Portland Health Care System, Portland, OR.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.